114 related articles for article (PubMed ID: 28224663)
1. Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.
Hinrichsen I; Ackermann A; Düding T; Graband A; Filmann N; Plotz G; Zeuzem S; Brieger A
Mol Carcinog; 2017 Jul; 56(7):1816-1824. PubMed ID: 28224663
[TBL] [Abstract][Full Text] [Related]
2. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
3. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
4. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
5. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
6. Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6.
Hegan DC; Narayanan L; Jirik FR; Edelmann W; Liskay RM; Glazer PM
Carcinogenesis; 2006 Dec; 27(12):2402-8. PubMed ID: 16728433
[TBL] [Abstract][Full Text] [Related]
7. Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1.
Hinrichsen I; Ernst BP; Nuber F; Passmann S; Schäfer D; Steinke V; Friedrichs N; Plotz G; Zeuzem S; Brieger A
Mol Cancer; 2014 Jan; 13():11. PubMed ID: 24456667
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage.
Ye J; Zhou Y; Weiser MR; Gönen M; Zhang L; Samdani T; Bacares R; DeLair D; Ivelja S; Vakiani E; Klimstra DS; Soslow RA; Shia J
Hum Pathol; 2014 Dec; 45(12):2430-6. PubMed ID: 25311944
[TBL] [Abstract][Full Text] [Related]
10. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.
Xia M; Singhi AD; Dudley B; Brand R; Nikiforova M; Pai RK
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):399-406. PubMed ID: 27258561
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
12. Ionizing radiation, inflammation, and their interactions in colon carcinogenesis in Mlh1-deficient mice.
Morioka T; Miyoshi-Imamura T; Blyth BJ; Kaminishi M; Kokubo T; Nishimura M; Kito S; Tokairin Y; Tani S; Murakami-Murofushi K; Yoshimi N; Shimada Y; Kakinuma S
Cancer Sci; 2015 Mar; 106(3):217-26. PubMed ID: 25529563
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
15. Targeting mitochondrial DNA polymerase gamma for selective inhibition of MLH1 deficient colon cancer growth.
Somuncu B; Ekmekcioglu A; Antmen FM; Ertuzun T; Deniz E; Keskin N; Park J; Yazici IE; Simsek B; Erman B; Yin W; Erman B; Muftuoglu M
PLoS One; 2022; 17(6):e0268391. PubMed ID: 35657956
[TBL] [Abstract][Full Text] [Related]
16. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting DNA-PK
Mamo T; Mladek AC; Shogren KL; Gustafson C; Gupta SK; Riester SM; Maran A; Galindo M; van Wijnen AJ; Sarkaria JN; Yaszemski MJ
Biochem Biophys Res Commun; 2017 Apr; 486(2):307-313. PubMed ID: 28300555
[TBL] [Abstract][Full Text] [Related]
19. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
20. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
